Literature DB >> 235398

Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment.

C Bengtsson, G Johnsson, C G Regårdh.   

Abstract

Plasma levels and the effect of orally administered metoprolol on the resting arterial blood pressure and heart rate have been studied during acute and steady-state conditions in patients with mild hypertension. The patients receiving an 80-mg dose had a mean maximum plasma level of about 100 ng/ml plasma in single-dose studies and about 140 ng/ml plasma during steady-state conditions. The corresponding values for the patients on the 50-mg dose were about 60 and 100 ng/ml plasma, respectively. The maximum concentrations were reached 1 hr after administration. After the single dose the elimination half-life of metoprolol in plasma was 4.3 plus or minus 0.7 hr in the patients receiving the 80-mg dose and 3.8 plus or minus 0.3 hr in the other group. The difference was not statistically significant. The elimination half-life in the plasma was about the same in the single-dose study and during steady state in both groups. The morning dose induced a decrease of the systolic blood pressure whereas the diastolic blood pressure was not significantly different from that recorded immediately before administration of metoprolol. For the 80-mg dose the systolic pressure dropped from 167 plus or minus 4 to 146 plus or minus 4 mm Hg in the single dose study and from 160 plus or minus 8 to 140 plus or minus 4 mm Hg at steady state. The corresponding values for the 50-mg dose were 150 plus or minus 3 to 135 plus or minus 3 mm Hg and 144 plus or minus 3 to 138 plus or minus 3 mm Hg, respectively. In experiments with placebo the systolic blood pressure was not significantly changed. There was no correlation between the plasma levels and the effect on the systolic blood pressure. Both doses of metoprolol markedly reduced the heart rate after the single dose as well as at steady state. The effect was linearly related to the logarithm of the plasma concentration, and the relationship was virtually the same as obtained previously for the effect on exercise heart rate in healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 235398     DOI: 10.1002/cpt1975174400

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  34 in total

Review 1.  Hypertension: which beta-blocker?

Authors:  H J Waal-Manning
Journal:  Drugs       Date:  1976-12       Impact factor: 9.546

Review 2.  Metoprolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-11       Impact factor: 9.546

Review 3.  The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future.

Authors:  B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

Review 4.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

5.  Plasma metoprolol concentrations in young, old and hypertensive subjects.

Authors:  M J Kendall; D Brown; R A Yates
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

6.  Evaluation of activity inotropic of a new steroid derivative using an isolated rat heart model.

Authors:  Figueroa-Valverde Lauro; Díaz-Cedillo Francisco; García-Cervera Elodia; Pool-Gómez Eduardo; López-Ramos Maria; Rosas-Nexticapa Marcela; Hau-Heredia Lenin; Sarabia-Alcocer Bety; Campos-Ramos Landy
Journal:  Int J Clin Exp Med       Date:  2014-05-15

7.  Long term treatment of moderate hypertension with the beta1-receptor blocking agent metoprolol. I. Effect on maximal working capacity, plasma catecholamines and renin, Urinary aldosterone, blood pressure and pulse rate under basal conditions.

Authors:  B G Hansson; J F Dymling; H Hedeland; U L Hulthén
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

8.  Development of a sustained-release microcapsule for delivery of metoprolol succinate.

Authors:  Li Song; Shengjiang He; Qineng Ping
Journal:  Exp Ther Med       Date:  2017-03-21       Impact factor: 2.447

9.  Comparison between atenolol and nadolol in essential hypertension at rest and on exercise.

Authors:  R G Wilcox; J R Hampton
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

10.  Pafenolol, a new beta 1-selective blocking agent, in mild hypertension. Result of an inpatient study and a subsequent outpatient follow-up.

Authors:  J A Sigurdsson; C Bengtsson; T Bjurö
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.